Brooks Laboratories Limited is an India-based pharmaceutical manufacturing company that operates on a contract basis. Incorporated in 2002, the company holds EU GMP & ISO 9001:2008 certifications, positioning itself as a key player in the manufacturing and marketing of pharmaceutical formulations. Its primary focus lies within the critical care segment, encompassing a range of pharmaceutical products, including active pharmaceutical ingredients (APIs) and intermediaries.
The company was established in 2002 and is headquartered in Mumbai, India. Its registered office is located at Village Kishanpura, Nilagarh Road, Baddi, Solan, Himachal Pradesh. Brooks Laboratories is listed on the National Stock Exchange (NSE) under the symbol BROOKS and on the Bombay Stock Exchange (BSE) with the code 533543. The International Securities Identification Number (ISIN) for the company is INE650L01011.
Brooks Laboratories specializes in the manufacturing of a diverse array of pharmaceutical dosage forms across various therapeutic categories. The company's production capabilities include:
- Dosage Forms:
- Injections (Liquid and Dry Powder)
- Tablets
- Dry Syrup
- Eye/Ear Drops
- Specialized Product Categories:
- Carbapenem Category:
- Imipenem 250mg + Cilastatin 250mg
- Imipenem 500mg + Cilastatin 500mg
- Meropenem 250mg
- Meropenem 500mg
- Meropenem 1000mg + Sulbactam 500mg
- Meropenem 1000mg + Tazobactam 500mg
- Doripenem 500mg
- Penicillins: Available in injection, tablet, and dry syrup forms.
- General Category:
- Liquid Injections (e.g., Iron sucrose 100mg/5ml, Iron sucrose 50mg/2.5ml, Phenytoin sodium 50mg/ml)
- Dry Powder Injections
- Eye/Ear Drops
Brooks Laboratories has demonstrated mixed financial performance in recent periods, characterized by revenue growth alongside profitability challenges.
- Market Capitalisation: ₹438.85 Crores (as of recent data)
- Revenue: ₹94.9 Crores (TTM)
- Profit (TTM): ₹-20.6 Crores
While the company has shown strong revenue growth of 27% on a trailing twelve-month (TTM) basis, its pre-tax margin stands at 2%, and the Return on Equity (ROE) is -29%, indicating areas for improvement in profitability.
Recent Quarterly & Annual Performance:
- Q4 FY2025 (Quarter Ended Mar 2025): Reported a consolidated loss of ₹-1.46 Crores on a total income of ₹23.94 Crores.
- FY2024 (Year Ended Mar 2024): Posted a consolidated loss of ₹-19.59 Crores on a total income of ₹79.49 Crores.
Key Financial Metrics (TTM):
- PE Ratio: -44.38
- PB Ratio: 4.50
- TTM Profit After Tax: ₹-21 Crores
The company maintains a debt-free status, contributing to a strong balance sheet. This financial stability enables it to report stable earnings growth across different business cycles.
- Promoter Holding: 52.6% (as of March 2025). This represents a decrease from 63.59% as of September 2024.
52-Week Performance:
- 52-Week High: ₹202.80
- 52-Week Low: ₹72.51
- Highest Price Reached: ₹198.86
Returns:
- Last 3 Years Return: 13.3%
Technical Indicators:
- The stock is trading close to its 200-day Moving Average (DMA).
- It is approximately 13% above its 50-day Moving Average (DMA).
- To achieve significant upward movement, the stock needs to sustain its position above the 200-DMA levels.
O'Neil Methodology Metrics:
- EPS Rank: 9 (POOR - indicates inconsistency in earnings)
- RS Rating: 78 (FAIR - indicates recent price performance)
Brooks Laboratories operates within the highly competitive pharmaceutical sector, specifically focusing on contract manufacturing services. The company falls under the "Pharmaceuticals - Indian - Bulk Drugs & Formulations" industry classification. Its WHO GMP & ISO 9001:2008 certifications underscore its commitment to quality and regulatory compliance in contract manufacturing, marketing, and exports.
The company navigates typical industry challenges such as stringent regulatory compliance, maintaining high-quality standards, and facing competitive pricing pressures. However, its established certifications and strategic focus on the critical care segment offer distinct advantages within the contract manufacturing market.
Brooks Laboratories continues to manage challenging market conditions while upholding its manufacturing capabilities and essential regulatory certifications. Its debt-free financial standing provides significant flexibility, though enhancing profitability remains a critical focus area for achieving sustainable long-term growth.
